LY3361237 + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Lupus Erythematosus
Conditions
Systemic Lupus Erythematosus
Trial Timeline
Mar 7, 2022 → Dec 29, 2023
NCT ID
NCT05123586About LY3361237 + Placebo
LY3361237 + Placebo is a phase 2 stage product being developed by Eli Lilly for Systemic Lupus Erythematosus. The current trial status is terminated. This product is registered under clinical trial identifier NCT05123586. Target conditions include Systemic Lupus Erythematosus.
What happened to similar drugs?
10 of 20 similar drugs in Systemic Lupus Erythematosus were approved
Approved (10) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05123586 | Phase 2 | Terminated |
| NCT04975295 | Phase 1 | Completed |
| NCT03933943 | Phase 1 | Completed |
Competing Products
20 competing products in Systemic Lupus Erythematosus